HC Wainwright Weighs in on AnaptysBio FY2030 Earnings

AnaptysBio, Inc. (NASDAQ:ANAB) – Stock analysts at HC Wainwright issued their FY2030 EPS estimates for shares of AnaptysBio in a research note issued to investors on Wednesday, March 4th. HC Wainwright analyst E. Bodnar anticipates that the biotechnology company will earn $7.67 per share for the year. HC Wainwright currently has a “Buy” rating and a $66.00 target price on the stock. The consensus estimate for AnaptysBio’s current full-year earnings is ($6.08) per share.

Several other research analysts also recently commented on the stock. Truist Financial raised their price objective on shares of AnaptysBio from $20.00 to $36.00 and gave the stock a “hold” rating in a report on Monday, November 10th. Guggenheim restated a “buy” rating on shares of AnaptysBio in a research report on Thursday, December 18th. Stifel Nicolaus raised their target price on shares of AnaptysBio from $56.00 to $85.00 and gave the stock a “buy” rating in a report on Thursday. Weiss Ratings reissued a “sell (d-)” rating on shares of AnaptysBio in a research note on Wednesday, January 21st. Finally, Wells Fargo & Company lifted their price target on shares of AnaptysBio from $51.00 to $81.00 and gave the company an “overweight” rating in a report on Wednesday, November 5th. Nine research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $71.89.

AnaptysBio Stock Down 1.0%

AnaptysBio stock traded down $0.58 during mid-day trading on Thursday, reaching $59.97. 193,325 shares of the company’s stock were exchanged, compared to its average volume of 470,587. The firm has a market capitalization of $1.66 billion, a PE ratio of -115.32 and a beta of 0.32. AnaptysBio has a one year low of $15.32 and a one year high of $63.47. The business’s fifty day simple moving average is $50.02 and its 200 day simple moving average is $38.65.

AnaptysBio (NASDAQ:ANAB) last issued its earnings results on Monday, March 9th. The biotechnology company reported $1.58 EPS for the quarter, beating analysts’ consensus estimates of $0.89 by $0.69. AnaptysBio had a negative return on equity of 1,101.24% and a negative net margin of 5.64%.The business had revenue of $108.25 million during the quarter, compared to analyst estimates of $87.09 million.

Institutional Trading of AnaptysBio

Hedge funds have recently made changes to their positions in the company. AQR Capital Management LLC lifted its holdings in AnaptysBio by 153.3% in the first quarter. AQR Capital Management LLC now owns 30,011 shares of the biotechnology company’s stock valued at $558,000 after acquiring an additional 18,165 shares during the last quarter. Savant Capital LLC acquired a new position in shares of AnaptysBio in the 2nd quarter valued at $241,000. Los Angeles Capital Management LLC acquired a new position in shares of AnaptysBio in the 2nd quarter valued at $334,000. Creative Planning lifted its position in AnaptysBio by 26.9% in the second quarter. Creative Planning now owns 16,854 shares of the biotechnology company’s stock valued at $374,000 after buying an additional 3,571 shares during the last quarter. Finally, Intech Investment Management LLC purchased a new position in AnaptysBio during the second quarter worth about $240,000.

Insider Transactions at AnaptysBio

In other AnaptysBio news, CFO Dennis Mulroy sold 2,515 shares of the firm’s stock in a transaction on Thursday, January 8th. The stock was sold at an average price of $44.71, for a total value of $112,445.65. Following the completion of the sale, the chief financial officer directly owned 21,852 shares of the company’s stock, valued at $977,002.92. This trade represents a 10.32% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Eric J. Loumeau sold 10,000 shares of AnaptysBio stock in a transaction on Wednesday, February 11th. The stock was sold at an average price of $54.00, for a total value of $540,000.00. Following the transaction, the insider owned 12,835 shares in the company, valued at approximately $693,090. This represents a 43.79% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 156,280 shares of company stock valued at $7,254,939. 33.50% of the stock is currently owned by company insiders.

AnaptysBio announced that its board has authorized a stock buyback plan on Friday, November 21st that authorizes the company to repurchase $100.00 million in shares. This repurchase authorization authorizes the biotechnology company to buy up to 9.6% of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s board believes its shares are undervalued.

More AnaptysBio News

Here are the key news stories impacting AnaptysBio this week:

• Positive Sentiment: Stifel Nicolaus raised its price target sharply to $85 and reiterated a Buy rating, implying meaningful upside versus recent levels — a notable institutional upshift that can attract buyers and support the rally. Stifel Raises PT to $85
• Positive Sentiment: HC Wainwright boosted its target to $66 (Buy) and published a very bullish FY2030 EPS projection (~$7.67), signaling strong analyst conviction about longer‑term earnings potential. Analyst upgrades like this add momentum. H.C. Wainwright PT Raise & Estimates
• Positive Sentiment: Barclays nudged its target to $79 with an Overweight rating — another institutional signal supporting demand for the shares. Barclays Raises PT to $79
• Positive Sentiment: Q4 results beat expectations: EPS $1.58 vs. $0.89 est., and revenue $108.3M vs. $87.1M est. The upside to both top and bottom line reduces near‑term execution risk and helps justify higher analyst targets. Q4 Earnings Beat
• Positive Sentiment: Management confirmed the planned spin‑off of its biopharma portfolio into a new public company, “First Tracks Biotherapeutics,” targeted for Q2 2026. A separation can unlock value by letting each business be valued on its own merits. Spin‑off Announcement
• Positive Sentiment: GSK’s Jemperli reported strong commercial performance (Q4 growth), and Anaptys highlighted expected royalty upside — management sees >$390M annualized royalties to Anaptys at peak GSK guidance, which supports longer‑term revenue visibility. Jemperli Royalty Outlook
• Neutral Sentiment: Reports show short interest figures as effectively zero/unchanged — likely a data anomaly and not a meaningful driver of price action. Short Interest Data
• Negative Sentiment: Despite the beat, the company still reports a negative net margin and negative return on equity, and consensus models expect losses in the near term (previous consensus for the fiscal year was negative EPS). These fundamentals are a reminder of inherent biotech execution and commercialization risk. Q4 Release & Financials

About AnaptysBio

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.